Oxytocin — Complete Research Guide (2026)

Last updated 2026-06-30

What is Oxytocin?

Oxytocin (brand names Pitocin and Syntocinon) is a synthetic form of the nine-amino-acid posterior-pituitary hormone. It is approved for induction and augmentation of labour and for the prevention and treatment of postpartum haemorrhage (PPH).

It is the WHO-recommended first-line uterotonic and is supported by numerous Cochrane systematic reviews.

This is informational content about an approved medicine and is not medical advice.

How does Oxytocin work?

Oxytocin binds uterine oxytocin receptors, raising intracellular calcium to stimulate rhythmic myometrial contractions; receptor density increases markedly at term, heightening uterine sensitivity.

After delivery, sustained uterine contraction compresses the blood vessels of the placental bed to reduce bleeding. [INFOGRAPHIC: Oxytocin uterine-receptor contraction]

What does the research say about Oxytocin?

• A Cochrane review found prophylactic oxytocin during the third stage of labour roughly halved the risk of postpartum blood loss of 500 mL or more compared with placebo. ^[2]
• A Cochrane review of 61 trials in over 12,000 women found intravenous oxytocin increased the proportion achieving vaginal birth within 24 hours versus expectant management for labour induction. ^[1]
• In a network meta-analysis of uterotonics for preventing postpartum haemorrhage, oxytocin was confirmed effective and serves as the reference standard, with carbetocin and combination regimens among the most effective. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Intravenous oxytocin alone for cervical ripening and induction of labour — Alfirevic Z et al., Cochrane Database Syst Rev 2009. (Cochrane review (61 trials, >12,000 women))
• [2] Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage — Westhoff G et al., Cochrane Database Syst Rev 2013. (Cochrane review)
• [3] High-dose versus low-dose oxytocin infusion regimens for induction of labour at term — Budden A et al., Cochrane Database Syst Rev 2014. (Cochrane review)
• [4] Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis — Gallos ID et al., Cochrane Database Syst Rev 2018. (Cochrane network meta-analysis)
• [5] Active versus expectant management for women in the third stage of labour — Begley CM et al., Cochrane Database Syst Rev 2019. (Cochrane review)

Dosing context

In approved obstetric use, oxytocin is given by trained clinicians as a diluted, titrated intravenous infusion for induction or augmentation, or as an IV/IM dose (commonly 10 IU) for third-stage prophylaxis and treatment of postpartum haemorrhage.

These are approved-product, hospital-administered parameters described for context only and are not personal medical advice.

Side effects & safety profile

Common dose-related risks include uterine tachysystole (excessive contraction) that can cause abnormal fetal heart-rate patterns; because oxytocin has mild antidiuretic activity, prolonged high-dose infusion with large volumes of electrolyte-free fluid can cause water intoxication and hyponatraemia.

It should be given only as a controlled, titrated infusion or bolus by trained clinicians with continuous uterine and fetal monitoring.

Stacking & combinations

For preventing or treating postpartum haemorrhage, oxytocin is sometimes combined with or compared against other uterotonics such as ergometrine, misoprostol or carbetocin under obstetric protocols.

Finding Oxytocin vendors

User reviews

Frequently asked questions

References

1. [1] Intravenous oxytocin alone for cervical ripening and induction of labour — Alfirevic Z et al., Cochrane Database Syst Rev 2009. PMID: 19821304. View sourceStudy: Cochrane review (61 trials, >12,000 women)Intravenous oxytocin increased vaginal births within 24 hours versus expectant management for labour induction.
2. [2] Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage — Westhoff G et al., Cochrane Database Syst Rev 2013. PMID: 24173606. View sourceStudy: Cochrane reviewProphylactic oxytocin in the third stage reduced postpartum haemorrhage of 500 mL or more compared with placebo.
3. [3] High-dose versus low-dose oxytocin infusion regimens for induction of labour at term — Budden A et al., Cochrane Database Syst Rev 2014. PMID: 25300173. View sourceStudy: Cochrane reviewHigher-dose oxytocin regimens may shorten labour but increase uterine hyperstimulation compared with low-dose regimens.
4. [4] Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis — Gallos ID et al., Cochrane Database Syst Rev 2018. PMID: 29693726. View sourceStudy: Cochrane network meta-analysisConfirmed oxytocin's efficacy for PPH prevention, with carbetocin and combination regimens ranking among the most effective.
5. [5] Active versus expectant management for women in the third stage of labour — Begley CM et al., Cochrane Database Syst Rev 2019. PMID: 30754073. View sourceStudy: Cochrane reviewActive management, including a uterotonic such as oxytocin, reduced severe primary postpartum haemorrhage versus expectant management.